Search Results

How to Denervate With Current Renal Denervation Device Iterations

A step-by-step guide to renal denervation for the treatment of hypertension.

By Brian Fulton, MD; Jay Giri, MD, MPH; Debbie L. Cohen, MD; Herbert D. Aronow, MD, MPH; and Taisei Kobayashi, MD

Ask The Experts: How Does PE Clot Location/Distribution Affect Your Therapy Decision-Making?

Reflections on how device selection and therapeutic approach for pulmonary embolism are impacted by factors such as thrombus location, clot burden, and patient risk profile.

With Taisei Kobayashi, MD; Riyaz Bashir, MD, FACC, RVT; and Kenneth Rosenfield, MD, MHCDS

The State of Reimbursement for Renal Denervation in the United States

As renal denervation is adopted across the United States for patients with uncontrolled or resistant hypertension, the dubious state of reimbursement presents a barrier to both health systems and patients seeking the procedure.

By Catherine Vanchiere, MD, MA; Tayyab Shah, MD; Debbie L. Cohen, MD; Jay Giri, MD, MPH; Brian Fulton, MD; and Taisei Kobayashi, MD

Renal Denervation: Where We Stand After the FDA Panels

Experts’ thoughts on what defines a clinically meaningful reduction in blood pressure, roles of office-based and ambulatory blood pressure monitoring, ideal candidates for renal denervation and patient preference as a driver for the procedure, options that could meet the FDA's request for more data, and applying a team-based approach to screening and treatment.

With Ajay J. Kirtane, MD, SM; Eric A. Secemsky, MD, MSc, RPVI, FACC, FSCAI, FSVM; and Taisei Kobayashi, MD

Emerging Options for Aortic Regurgitation

By Matti Adam, MD, and Jonathan Curio, MD

Contemporary Mitral & Tricuspid Therapies

By Gagan D. Singh, MD, and Azeem Latib, MD

Modern Clinical Trials Spotlight

By Ori Ben-Yehuda, MD

Radiation and Musculoskeletal Safety

By Eric A. Secemsky, MD, MSc